Messages in brief
New European pharmacovigilance legislation
The following innovations are planned throughout Europe:
Risk and risk managementAllmedicinal products carry known and unknown risks at the time of…
Use of combined oral contraceptives (COCs)
The occurrence of venous thromboembolic events (VTE) is a rare but long-known adverse effect of combined oral contraceptives (COCs), which is…
Anapen (Epinephrin)
Anapen (active ingredient: epinephrine) has been approved for the treatment of a state of shock (anaphylactic emergency) in some European member…
EMA makes safety data publicly available
As part of its transparency policy, the EMA has made data on adverse reaction reports publicly available at www.adrreports.eu since May 31, 2012. This…
Federal Minister Stöger opens site
On this occasion, the minister reminded the audience that many countries in Europe are cutting back on health care, and sometimes health care…
Girl's Day 2012: Girls at OMCL
Around 30 girls between the ages of ten and 16 learned more about the assessment and control of medicines on today's Girl's Day.
They were able to…
BASG Consultation
The increasing complexity of the legal materials AMG and MPG, in particular the areas of clinical testing, medical devices in general, in vitro…
Deadline for the extension of the authorisation of existing products
We would like to point out that the deadline set in accordance with Section 94c(10) of the Austrian Medicines Act, Federal Law Gazette No. 185/1983,…
Caution with methotrexate dosing in autoimmune disease.
Methotrexate (MTX) is used to treat severe forms of psoriasis, autoimmune diseases (e.g., rheumatoid arthritis), and various tumor diseases. It is…
Telephone inquiries / calls on behalf of AGES
The BASG / AGES Medical Market Inspectorate became aware that pharmaceutical companies were contacted by telephone in the name of AGES, or by persons…
